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Background: The use of organ sparing strategies to treat penile cancer (PC) is currently supported by 
evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still 
represents up to 15–20% of primary tumor treatments in PC patients. The aim of the study was to evaluate 
efficacy in terms of overall survival (OS) and disease-free survival (DFS) of radical penectomy in PC patients. 
Methods: Data from a retrospective multicenter study (PEnile Cancer ADherence study, PECAD Study) 
on PC patients treated at 13 European and American urological centers (Hospital “Sant’Andrea”, Sapienza 
University, Roma, Italy; “G.D’Annunzio” University, Chieti and ASL 2 Abruzzo, Hospital “S. Pio da 
Pietrelcina”, Vasto, Italy; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, 
USA; Hospital of Budapest, Hungary; Department of Emergency and Organ Transplantation, Urology and 
Andrology Unit II, University of Bari, Italy; Hospital “Spedali Civili”, Brescia, Italy; Istituto Europeo di 
Oncologia, University of Milan, Milan, Italy; University of Modena & Reggio Emilia, Modena, Italy; Hospital 
Universitario La Paz, Madrid, Spain; Ceara Cancer Institute, Fortaleza, Brazil; Virginia Commonwealth 
University, Richmond, VA, USA; Aristotle University of Thessaloniki, Thessaloniki, Greece; Maria 
Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland) between 2010 and 2016 were used. Medical 
records of patients who specifically underwent radical penectomy were reviewed to identify main clinical and 
pathological variables. Kaplan-Meier method was used to estimate 1- and 5-year OS and DFS.
Results: Of the entire cohort of 425 patients, 72 patients (16.9%) treated with radical penectomy were 
extracted and were considered for the analysis. The median age was 64.5 (IQR, 57.5–73.2) years. Of all, 41 
(56.9%) patients had pT3/pT4 and 31 (43.1%) pT1/pT2. Moreover, 36 (50.0%) were classified as pN1–3 
and 5 (6.9%) M1. Furthermore, 61 (84.7%) had a high grade (G2–G3) with 6 (8.3%) positive surgical 
margins. The 1- and 5-year OS rates were respectively 73.3% and 59.9%, while the 1- and 5-year DFS rates 
were respectively 67.3% and 35.1%.
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Introduction
Penile cancer (PC) and its most common histopathological 
subtype, squamous cell carcinoma (SCC), are uncommon 
neoplasms in developed nations, ranging from 0.6 to 6.8 per 
100,000 men (1,2), accounting for an estimated 0.2–0.4% 
of malignancies in men (1-5). Notwithstanding its low 
incidence, this cancer was diagnosed in 2018, in the United 
States, in more than 2,000 patients and was the cause of 
death in approximately 400 deaths (6,7).
This neoplasia when diagnosed could require aggressive 
treatment resulting in significant morbidity, with negative 
impact on quality of life, including its devastating role on 
the psychology and sexuality of patients (8-10). 
Age at diagnosis, stage, histologic grade and subtype of 
the tumor, presence of perineural and lymphatic infiltration, 
lymph node (LN) involvement are considered prognosis-
key issues (11,12).
The gold standard treatment for localized PC is 
surgery. Although in the case of premalignant conditions 
or PC early stages an organ sparing surgery (OSS) 
(glans resurfacing, laser ablation, topical agents, i.e., 
5-fluorouracil and imiquimod, glansectomy, local excision) 
may be applicable, partial or radical/total penectomy with 
perineal urethrostomy combined with radical inguinal 
lymphadenectomy still remains the recommended option for 
locally advanced and advanced invasive disease (11,13-17).
The OSS is undoubtedly an attractive option, but is 
still underused because of a presumed high risk of local 
recurrence (18,19). Mossanen et al. questioned the use 
of radical penectomy for optimal oncological control 
supporting the idea that partial penectomy may ensure 
overlapping survival rates to radical approach (20). 
Moreover, Chipollini et al. focused on the need of an 
appropriate follow up program in patients of pT2 tumor 
treated with OSS (21). Despite general interest for 
expanding indications of OSS, radical penectomy still 
represents up to 15–33% of treatments offered to PC 
patients (18,22-24).
Due to the rarity of PC, without level 1 evidence, in the 
absence of prospective and randomized studies to guide 
decision making, it is difficult to exactly define the oncology 
efficacy of one surgical option over the others. 
The objective of this retrospective multi-institutional 
international study is to present our overall experience with 
radical penectomy for SCC.
Methods
Study population and main characteristics of interest
Following approval by the local ethical committees we 
retrospectively reviewed the clinical notes of all patients 
with PC that underwent surgical treatment in 13 European 
and American Centers from 2010 to 2016 (Penile Cancer 
Adherence study, PECAD Study).  Demographics, 
patient’s comorbidities, history of circumcision, site and 
size of the primary lesion and primary local therapy, LN 
management and histopathology data were collected and 
analyzed. The type of surgical procedure was decided 
upon after taking into consideration surgeon’s and patient’s 
preferences and the European Association of Urology 
(EAU) Guidelines on PC. No perioperative chemotherapy 
or postoperative radiation was used for the management of 
the penile lesions. Staging was performed using physical 
examination and cross-sectional imaging with computed 
tomography (CT) and/or magnetic resonance imaging 
(MRI). Histopathological reports were provided by 
local genitourinary pathologists and according to local 
institutional protocol and the American Joint Committee 
on Cancer (AJCC)/International Union Against Cancer 
(UICC) 2009 TNM Classification for stage and grade. 
Only SCC cases were considered. Follow-up was done with 
periodical physical examination and imaging according to 
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stage and risk stratification for all patients
Survival endpoints
The main survival endpoint of the study was to describe 
disease-free survival (DFS) rates. Secondary endpoint was 
to describe overall survival (OS). We defined follow-up as 
the time interval between surgery and disease recurrence 
or death for any cause. For patients in whom none of the 
events occurred, we defined the follow-up time interval as 
the period from surgery to the last follow-up visit.
Statistical analysis
Descriptive statistics relied on median and interquartile 
range (IQR) to summarize quantitative data, while 
frequency and proportions summarized qualitative data. 
Kaplan-Meier method was used to estimate DFS and OS 
rates at 1 and 5 years. Cox proportional hazards model were 
used to estimate the hazard ratios of main predictors of 
disease recurrence. 
All statistical analyses were performed using R Statistical 
Software (version 3.5.3; R Foundation for Statistical 
Computing, Vienna, Austria). All tests were two-tailed, and 
a P value <0.05 was considered indicative of a statistically 
significant association.
Results
The PECAD registry included 481 patients. Of all 84 
(17.4%) underwent radical penectomy. After applying 
inclusion and exclusion criteria, 72 patients were retained 
in the study cohort (we excluded those on whom we had no 
information on the grade of the tumor or lost on follow-
up). The median age was 64.5 (IQR, 57.5–73.2) years. Of 
all, 43.1% were circumcised, approximately half of the 
patients had tumors localized both to the foreskin and 
glands (54.2%), while none of them had tumors located in 
the shaft (Table 1). 
Moreover, just over half of patients harbored pT3/
pT4 stages (56.9%). At presentation 55.6% of patients 
had palpable inguinal LN. Inguinal lymph node dissection 
(LND) was performed in 51 (70.8%) patients (with 
adherence to the EAU guidelines of 97%). One third of the 
patients who underwent LND harbored pN2 stage (30.0%).
At a median follow up of 11.7 months (IQR, 8.2–25.6), 
29 (40.3%) patients experienced disease recurrence. Among 
them 11 (15.3%) local and 14 (19.4%) had a systemic 
Table 1 Descriptive characteristics of the included patients
Variable Value, median (IQR) or n (%)
Age 64.5 (57.5–73.2)
Follow up 11.7 (8.2–25.6)
Circumcision 31 (43.1) 
Diabetes 6 (8.3) 
Hypertension 17 (23.6) 
Cardiovascular disease 6 (8.3) 
Dyslipidemia 3 (4.2) 
Obesity 7 (9.7) 
Site 
Foreskin 1 (1.4) 
Glands 32 (44.4) 
Both 39 (54.2) 
Positive clinical node 40 (55.6) 
T-stage 
pT1/2 31 (43.1) 
pT3/4 41 (56.9) 
N-stage 
pN0 14 (19.4) 
pN1 10 (13.9) 
pN2 19 (26.4) 
pN3 7 (9.7) 
pNx 22 (30.6) 
M-stage 
M0 48 (66.7) 
M1 5 (6.9) 
Mx 19 (26.4) 
Grade 
G1 11 (15.3) 
G2 43 (59.7)
G3 18 (25)
Positive margins 6 (8.3)
Vascular invasion 24 (33.3) 
Lymphovascular invasion 25 (34.7)
Lymphadenectomy 51 (70.8)
IQR, interquartile range.
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recurrence. Thirteen (18.1%) patients underwent an 
adjuvant chemotherapy cycle while seven patients (9.7%) 
continued therapeutic plan with subsequent radiotherapy. 
The 1- and 5-year DFS rates were 67.3%±6.3% and 
35.1%±8.8%, respectively (Figure 1). In univariable analyses 
the only predictor of disease recurrence was the pN stage. 
Indeed, higher recurrence rates were recorded in pN2 
[hazard ratio (HR): 3.5, 95% confidence interval (CI): 
1.07–11.39, P=0.038] and pN3 (HR: 4.22, 95% CI: 1.04–
17.12; P=0.043) patients, compared their pN0 counterpart. 
Overall, 19 (26.4%) patients died. The 5-year OS rates were 
59.9%±7.9% (Figure 2). 
Discussion
The radical surgical approach in PC has historically been 
considered the gold standard in the subgroup of patients 
at intermediate and high risk (anatomical-pathological 
stage ≥ pT1) with it a not indifferent “baggage” in terms 
of mortality, morbidity, physical, psychological and sexual 
impact. This therapeutic choice is emerging, evaluating data 
available in the literature, as the first indication furthermore 
in a significant percentage of subjects classified as low grade, 
early stage or in case of precancerous lesions, therefore in 
a subset of possible candidates for a less mutilating and less 
aggressive approach such us organ-sparing surgery (OSS). 
Radical treatment option is going to represent therefore, 
up to 30% to date, particularly in non-reference centers, 
with low volume of PC patients (18,22-24). In recent years, 
therefore, it is not surprising that more and more interests 
and attentions have focused around the OSS of PC with all 
his arrows and weapons, ranging from laser therapy with 
neodymium-doped yttrium aluminum garnet or carbon 
dioxide mediums to OSS like Mohs surgery, circumcision, 
glansectomy, glans resurfacing or partial penectomy 
approach trying to expand the therapeutic window more and 
more in favor of this preservation techniques (18,21,25,26).
In our study we exported, from the total pool present in 
a larger database which counts 425 total subjects diagnosed 
with PC, the data of 72 patients treated in the first instance 
with radical surgery. Our work aimed at evaluating the 
effectiveness in terms of OS and DFS at 1 and 5 years, 
focusing on an average follow-up period of 11.7 months. 
Our data has exposed the aggressiveness and poor prognosis 
of this neoplasm, despite the use of a radical approach. The 
OS rate was only slightly higher than 59% at 5 years, with a 
5-year DFS rate of just 35%. These results are in agreement 
with what reported by the current literature. Zhu et al. in 
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Figure 1 Disease-free survival in the study population.
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their manuscript assessed the PC specific survival (PCSS) 
following conservative penile sparing surgery (PSS) and 
more aggressive surgery ranged from partial penectomy to 
radical and total penectomy in a population of 699 patients 
with PC stage pT1 (18), isolated from a total number of 
1,292 patients with penile malignancies. In the 699 pT1 
subgroup, 265 (37.9%) patients underwent local tumor 
excision (LTE) while the remaining 434 (62.1%) was 
offered the more aggressive partial/total penectomy. The 
overall cancer mortality (OCM) resulting in the subgroup of 
patients treated with an aggressive approach was 40.7% with 
a PC specific mortality (PCSM) of 11.7%, numbers not far 
from our results. In the study published by Patel et al. (26), 
the author analyzed 220 cases of Australian patients 
diagnosed with PC, extrapolating data from a large database, 
the Central Cancer Registry, from 2001 to 2009, also 
comparing the low volume centers of surgical procedures 
for PC, with more experienced centers and greater number 
of surgical interventions on this pathology. On the sample of 
the 220 patients, Radical penile procedures (partial or total 
penectomy) were performed in 70% of the cases. Manish I. 
Patel then divided the centers involved in “Teaching” and 
“Non-teaching” centers and low (<4 procedures in 10 years) 
and high (>4 procedures in 10 years) volume of surgical 
interventions. The “Non-teaching” hospitals, where almost 
all were low-volume centers of procedures/year, the number 
of radical procedures reached and exceeded the percentage 
of 73%, against 65% of the structures defined as “Teaching” 
in a non-statistically significant manner (P=0.07). Again, in 
this work, survival in terms of median OS and 5-year OS 
was assessed, resulting respectively at 86.1% and 70.6%, 
significantly higher value than that extrapolated from the 
study of Zhu et al. but not too far from the percentages 
obtained in our experience. In the retrospective study by 
Beech et al. of 2015 (23), the authors published their ten-
year experience (2005–2015) on 42 patient PCs and a 
follow-up of 25 months; passing through the LN staging, 
the patients were stratified as clinically negative LNs (32 
patients—cN0) and clinically positive nodes (10 patients—
cN1). The surgical approach chosen was excisional biopsy 
in 29%, partial penectomy in 38% and total penectomy in 
33% of cases. The OS was 60% in this case at 102 months.
Moreover, there is also the scientific microcosm 
that orbits this rare neoplasm; guidelines established 
on this cancer are constructed on a small number and 
methodologically weak publications result in low evidence 
level, weak degrees of recommendation and limited 
adoption of itself. We detected an adherence to the EAU 
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guidelines of 71% for <T2 stage PC, in a Swedish study (22) 
and in percentage of 91.4% in a study that involved more 
of 6,000 patients, structured in the United States, based 
on National Comprehensive Cancer Network (NCCN) 
guidelines for the management of the primary tumor (27). 
It means we are still treating smaller penile tumors with 
more radical surgery than necessary.
LN staging and management is undoubtedly an 
important indicator of survival in PC. EAU guidelines 
suggest lymphadenectomy or biopsy of sentinel node (SN) in 
cN0 with pT1b, T2–T4, and in all case of cN1/cN2 (28-30). 
In literature only a low proportion of patients are really 
treated with LND. Reasons for this should probably due 
to the high rate of difficulty encountered in the procedural 
technique combined with the non-negligible mortality 
and morbidity (31). More recent studies however found an 
increase in LND rates (31). This is in line with the results 
of our study which showed a 70% percentage of approach 
with LND.
Our findings also have shown agreement with previously 
published data to consider and define the N stage as an 
important survival prognostic indicator, the strongest 
predictor of poor prognosis. In the Canadian experience of 
Beech at al. 10 patients presented with clinically palpable 
nodal disease; 3 were deemed inoperable and the remaining 
7 underwent radical lymphadenectomy with 5 patients pN3 
and 2 pN0. In the pN3 group, 4 died and the last survived 
28 months before having a penile recurrence which led to a 
salvage total penectomy.
For all these reasons we considered the objective of 
focusing the attention on this setting of patients undergoing 
radical surgery to be valid and interesting. As for our 
knowledge of recent literature, this population-based study 
we presented is the first manuscript entirely focused on 
radical penectomy patients, extrapolated from a multicenter, 
international database, which certainly boasts a good 
number of examined patients.
The study in question certainly shows some limitations. 
One is certainly the heterogeneity of the PC patient sample 
in terms of stage, disease progression, surgical skills and 
learning curves in different phases within the different 
first surgeons involved in the procedures. However, this in 
relation to the character and multicentric print of the work 
that has enlisted 13 centers between Europe and America. 
The numeric sample of patients (analyzed retrospectively) 
may seem low but it is in our opinion valid considering 
the rarity of the tumor pathology of the PC. We have 
retrospectively considered only patients with the anatomo-
pathological squamous cell histotype (SCC), which however 
appear to be the most frequent histotype in patients with 
PC. We found systemic recurrences in 14 patients (19.4%) 
but unfortunately, we don’t know where exactly systemic 
recurrences were found.
The importance of this study is twofold: on the one 
hand there is an objective confirmation of high mortality 
and recurrence of the disease despite a cruel and radical 
approach even to the minor stage neoplasia, on the other 
this puts in the spotlight the gap, still important between 
the various and numerous scientific evidence, the attractive 
and publicized “mini invasive” or OSS techniques and the 
actual practice of urological surgical centers, where radical 
intervention represents a therapeutic option over-used even 
outside the boundaries of the guidelines.
Conclusions
These findings of our multi-institutional experience confirm 
the poor prognosis and the aggressive pattern of this cancer 
in line with the data currently in the literature, also with a 
radical penectomy approach. Our data have shown that at 
5 years, more than a third of patients do not survive and 
more than 60% report a disease recurrence, despite radical 
treatment and lymphadenectomy approach (that was carried 
out in more than 70% of patients). Furthermore, our data 
have highlighted and demonstrated that, to date, OSS 
techniques are more an attraction, a surgical mirage but not 
a real practical reality.
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